Roche: Sarepta Therapeutics Announces That U.S. FDA has Accepted Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy Montag, 28. November 2022 - 15:38

Investor Update

Sarepta Therapeutics Announces That U.S. FDA has Accepted Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta's Gene Therapy for Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

Dear Investor,

Please find attached a press release by Sarepta Therapeutics regarding the FDA acceptance of filing and priority review of our partnered DMD asset:

https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-us-fda-has-accepted-filing-and

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com	Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com